Allogene Therapeutics, Inc.
ALLO
$1.45
$0.053.57%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | -- | -- | -26.67% | 152.50% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.00% | -- | -- | -26.67% | 152.50% |
| Cost of Revenue | -17.73% | -2.75% | -18.83% | -34.87% | -27.52% |
| Gross Profit | 17.69% | 2.70% | 18.80% | 34.87% | 27.59% |
| SG&A Expenses | -9.90% | -4.15% | -13.16% | -8.56% | -17.99% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -15.85% | -3.13% | -17.53% | -29.86% | -25.45% |
| Operating Income | 15.83% | 3.10% | 17.50% | 29.86% | 25.50% |
| Income Before Tax | 30.64% | -6.43% | 16.25% | 34.98% | 16.42% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 30.12% | -6.43% | 16.25% | 34.98% | 16.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 30.12% | -6.43% | 16.25% | 34.98% | 16.42% |
| EBIT | 15.83% | 3.10% | 17.50% | 29.86% | 25.50% |
| EBITDA | 16.28% | 2.67% | 18.33% | 31.00% | 26.78% |
| EPS Basic | 44.15% | 14.70% | 35.30% | 44.43% | 28.43% |
| Normalized Basic EPS | 32.89% | 24.89% | 40.17% | 44.42% | 42.81% |
| EPS Diluted | 44.15% | 14.70% | 35.30% | 44.43% | 28.43% |
| Normalized Diluted EPS | 32.89% | 24.89% | 40.17% | 44.42% | 42.81% |
| Average Basic Shares Outstanding | 25.09% | 24.78% | 29.45% | 16.99% | 16.78% |
| Average Diluted Shares Outstanding | 25.09% | 24.78% | 29.45% | 16.99% | 16.78% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |